Celyad Oncology (LTS:0QFK) Other Current Payables: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QFK Celyad Oncology SA LTS:0QFK
33 GF Score
Price €0.24
GF Value €0.67
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology Other Current Payables?

Celyad Oncology LTS:0QFK -7.09% 33 Other Current Payables is €0.00 Mil as of Dec. 2025. GuruFocus rates LTS:0QFK with a GF Score™ of 33/100 and a GF Value™ of €0.67 (Possible Value Trap). The stock has 6 warning signs investors should review.

Celyad Oncology's Other Current Payables for the quarter that ended in Dec. 2025 was €0.00 Mil.

Celyad Oncology Other Current Payables Related Terms

Celyad Oncology Other Current Payables Historical Data

* Premium members only.

The historical data trend for Celyad Oncology's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology Other Current Payables Chart

Celyad Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Celyad Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0QFK
33GF Score
Celyad Oncology SA LTS:0QFK
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celyad Oncology Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.00 Mil mean?
Celyad Oncology (LTS:0QFK) has a Other Current Payables of €0.00 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Celyad Oncology and its competitors.
Is Celyad Oncology's Other Current Payables too high?
Celyad Oncology's current Other Current Payables is €0.00 Mil. Overall, Celyad Oncology has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Other Current Payables compare to VRTX and REGN?
Celyad Oncology's Other Current Payables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Celyad Oncology and its competitors. Celyad Oncology's current Other Current Payables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (LTS:0QFK) is currently considered Possible Value Trap. The stock's GF Value™ is €0.67, compared to a current price of €0.24 — trading 64.2% below its estimated fair value. The current Other Current Payables is €0.00 Mil. Celyad Oncology's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Celyad Oncology (LTS:0QFK), the current Other Current Payables is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celyad Oncology (LTS:0QFK) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of €0.24 is trading 64.2% below its estimated GF Value™ of €0.67. GuruFocus considers Celyad Oncology to be Possible Value Trap.

Key valuation signals for LTS:0QFK:

  • Other Current Payables: €0.00 Mil
  • GF Value™: €0.67 vs. price of €0.24 (64.2% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the LTS:0QFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
33GF Score

Get the complete analysis for LTS:0QFK

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.67
GF Value